Metastatic castration-resistant prostate cancer and the challenge of a patient with chronic kidney disease in hemodialysis
DOI:
https://doi.org/10.4322/acr.2018.011Keywords:
Prostate cancer, Dialysis, Docetaxel, Enzalutamide, Radium-223.Abstract
At a time when the population shows increasing longevity, entities such as cancer and chronic kidney disease (CKD) are more frequently connected. In the United States, approximately 6% of the patients on hemodialysis have cancer. The challenge to manage oncologic patients with CKD in a hemodialytic program represents a great shortage of available information on the choice of the best drug, timing, dosage adjustments, dialysis method, and treatment safety. We present the case of a patient with prostate cancer and terminal CKD in hemodialysis, and the treatment sequence after the development of resistance to hormonal blockade therapy, which included docetaxel, enzalutamide, and radium-223.Downloads
Download data is not yet available.
Published
2018-06-13
Issue
Section
Article / Clinical Case Report
License
Copyright
Authors of articles published by Autopsy and Case Report retain the copyright of their work without restrictions, licensing it under the Creative Commons Attribution License - CC-BY, which allows articles to be re-used and re-distributed without restriction, as long as the original work is correctly cited.
How to Cite
Simões, J., Augusto, I., Meireles, S., Vendeira, L., & Silva, C. (2018). Metastatic castration-resistant prostate cancer and the challenge of a patient with chronic kidney disease in hemodialysis. Autopsy and Case Reports, 8(2), e2018011. https://doi.org/10.4322/acr.2018.011